Astellas Pharma Europe Ltd.
Quick facts
Marketed products
- Eligard · Oncology
Phase 3 pipeline
- FK506E · Immunology
FK506E is a calcineurin inhibitor that suppresses T-cell activation by blocking the phosphatase calcineurin, preventing IL-2 production and T-cell proliferation.
Phase 2 pipeline
- Betmiga® · Urology
Betmiba works by increasing the levels of magnesium in the urine, which helps to prevent kidney stones. - Qutenza exposure
- Tacrolimus prolonged release
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Astellas Pharma Europe Ltd.
What are Astellas Pharma Europe Ltd.'s marketed drugs?
Top marketed products include Eligard.
What is Astellas Pharma Europe Ltd.'s pipeline?
Astellas Pharma Europe Ltd. has 1 drugs in Phase 3, 3 in Phase 2, 0 in Phase 1. Late-stage candidates include FK506E.
Related
- Eligard · Oncology
- Sector hub: All tracked pharma companies